Targeting pancreatic cancer with TCR-engineered T cells

被引：0

作者：

Greenberg, Philip D. ^{[1
]}

Anderson, Kristin G. ^{[1
]}

Egan, Dan ^{[1
]}

Hingorani, Sunil R. ^{[1
]}

Nezi, Luigi ^{[2
]}

Manzo, Teresa ^{[2
]}

Oda, Shannon K. ^{[1
]}

Paulson, Kelly G. ^{[1
]}

Perret, Rachel ^{[1
]}

Schmidt, Leah ^{[1
]}

Schmitt, Tom M. ^{[1
]}

Stromnes, Ingunn M. ^{[3
]}

Chapuis, Aude G. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[2] European Inst Oncol IEO, Milan, Italy

[3] Univ Minnesota, Seattle, WA USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 24期

关键词：

D O I：

10.1158/1538-7445.PANCA19-I11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

I11

引用

页数：2

共 50 条

[21] Effective method to generate TCR-engineered neoantigen-specific cytotoxic T cells
Nakamura, Yusuke
[J]. CANCER SCIENCE, 2018, 109 : 609 - 609
[22] Automated, closed, GMP-compliant manufacture of TCR-engineered T cells for therapy
Ogusuku, I. Elias Yonezawa
Lennartz, S.
Brandes, C.
Herbel, V.
Teppert, K.
Schaser, T.
Koutsoumpli, G.
Griffioen, G.
Johnston, I.
Lock, D.
[J]. HUMAN GENE THERAPY, 2022, 33 (23-24) : A102 - A102
[23] Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
Wachsmann, Tassilo L. A.
Meeuwsen, Miranda H.
Remst, Dennis F. G.
Buchner, Karen
Wouters, Anne K.
Hagedoorn, Renate S.
Falkenburg, J. H. Frederik
Heemskerk, Mirjam H. M.
[J]. BLOOD ADVANCES, 2023, 7 (20) : 6178 - 6183
[24] Automated manufacture of A NPM1 TCR-engineered T cells for AML therapy
Ogusuku, Isabella Elias Yonezawa
Herbel, Vera
Lennartz, Simon
Brandes, Caroline
Argiro, Eva
Fabian, Caroline
Hauck, Carola
Hoogstraten, Conny
Veld, Sabrina
Hageman, Lois
Teppert, Karin
Koutsoumpli, Georgia
Mockel-Tenbrinck, Nadine
Schaser, Thomas
de Groot, Rosa
Johnston, Ian C. D.
Lock, Dominik
[J]. MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32
[25] Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma
Hotblack, Alastair
Holler, Angelika
Piapi, Alice
Ward, Sophie
Stauss, Hans J.
Bennett, Clare L.
[J]. MOLECULAR THERAPY, 2018, 26 (06) : 1471 - 1481
[26] Targeting alpha fetoprotein with TCR engineered T cells in HCC
Gerry, Andrew
Sanderson, Joe
Maroto, Miguel
Ferronha, Tiago
Ranganathan, Sulabha
Norry, Elliot
Pandite, Lini
Amado, Rafael G.
Jakobsen, Bent K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells
Manfredi, Francesco
Abbati, Danilo
Cianciotti, Beatrice Claudia
Stasi, Lorena
Potenza, Alessia
Ruggiero, Eliana
Magnani, Zulma
Carnevale, Erica
Doglio, Matteo
Noviello, Maddalena
Tassi, Elena
Balestrieri, Chiara
Buonanno, Silvia
Clemente, Francesca
De Lalla, Claudia
Protti, Maria Pia
Mondino, Anna
Casorati, Giulia
Dellabona, Paolo
Bonini, Chiara
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (08) : 1992 - 2005
[28] FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2024, 23 (10) : 731 - 731
[29] Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes
Abate-Daga, Daniel
Hanada, Ken-ichi
Davis, Jeremy L.
Yang, James C.
Rosenberg, Steven A.
Morgan, Richard A.
[J]. BLOOD, 2013, 122 (08) : 1399 - 1410
[30] PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer
Li, Qiongshu
Liu, Muyun
Wu, Man
Zhou, Xin
Wang, Shaobin
Hu, Yuan
Wang, Youfu
He, Yixin
Zeng, Xiaoping
Chen, Junhui
Liu, Qubo
Xiao, Dong
Hu, Xiang
Liu, Weibin
[J]. ONCOLOGY LETTERS, 2018, 15 (04) : 5924 - 5932

← 1 2 3 4 5 →